Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 5,324 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Continuous Dose Clear all

Conditions: Advanced/Metastatic Solid Tumors
Interventions: Selicrelumab, Vanucizumab, Bevacizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 2 more

Conditions: HNSCC
Interventions: Cesium-131, Pembrolizumab; Device · Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 19 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: Postoperative Pain
Interventions: Lidocaine and ketamine, Lidocaine, Ketamine, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Solid Organ Malignancies, Adenoidcystic Carcinoma, Neuroendocrine Tumors
Interventions: Lenalidomide, Everolimus; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Status Epilepticus
Interventions: lorazepam or diazepam; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 3 Months to 18 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 12
States / cities: Davis, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more

Conditions: Biliary Cancer, Cholangiocarcinoma
Interventions: Gemcitabine, Irinotecan, Panitumumab; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rectal Cancer
Interventions: Endo-HDR (if randomized to this arm), capecitabine and IMRT (if randomized to this arm), IMRT (intensity modulated radiation therapy), FOLFOX6, Surgery; Radiation · Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 4
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 1 more

Conditions: Graves Disease
Interventions: WP1302, WP1302 placebo, methimazole; Drug · Combination Product
Lead sponsor: Worg Biotherapeutics Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Hunt, Arizona • Canoga Park, California • Littleton, Colorado + 4 more

Conditions: Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms, Neoplasms, Germ Cell and Embryonal
Interventions: Mithramycin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Paroxysmal Nocturnal Hemoglobinuria, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Relapsing Chronic Myelogenous Leukemia, Thrombocytopenia, Untreated Adult Acute Myeloid Leukemia
Interventions: bryostatin 1, sargramostim, laboratory biomarker analysis, pharmacological study; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Transplant
Interventions: Belatacept, Tacrolimus, Mycophenolate Mofetil/Sodium, Prednisone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 76 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 4 more

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Venetoclax, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Hollywood, Florida + 15 more

Conditions: Non Small Cell Lung Cancer
Interventions: Calcitriol; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Buffalo, New York

Conditions: Recurrent Head and Neck Cancer, Head and Neck Cancer, Head and Neck Neoplasms, Metastatic Cancer
Interventions: Durvalumab, Cetuximab; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: COVID-19
Interventions: Cyclosporine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma
Interventions: Oxaliplatin, Docetaxel, Leucovorin, Irinotecan, 5-Fluorouracil; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Colon Cancer, Rectal Cancer, Colorectal Cancer, Colorectal Cancer (CRC)
Interventions: fruquintinib, FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Denver, Colorado • Arlington Heights, Illinois • Columbia, Maryland + 11 more

Conditions: Metastatic Soft-tissue Sarcoma
Interventions: Cyclophosphamide, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2963016, LANTUS®, Oral Antihyperglycemic Medication; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more

Conditions: Anemia
Interventions: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 6
States / cities: Birmingham, Alabama • San Diego, California • Detroit, Michigan + 2 more

Conditions: Female Infertility Due to Diminished Ovarian Reserve
Interventions: Human Growth Hormone, Follicle Stimulating Hormone; Drug
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Postoperative
Interventions: Single shot interscalene nerve block, Continuous interscalene nerve block, Local Infiltration Analgesia (LIA); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pancreatic Cancer, Ductal Adrenocarcinoma, Exocrine Pancreatic Cancer
Interventions: PCI-27483, Gemcitabine; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 17
States / cities: Scottsdale, Arizona • Anaheim, California • Titusville, Florida + 13 more

Conditions: Pre-Eclampsia
Interventions: Human Albumin (colloid), Lactated Ringer's Injection (crystalloid), Edwards HemoSphere monitor with ClearSight-Acumen finger cuff; Drug · Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

Perioperative Lidocaine and Ketamine in Abdominal Surgery

Study of Everolimus (RAD001) in Combination With Lenalidomide

Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)

Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

Chemoradiation or Brachytherapy for Rectal Cancer

Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

Belatacept in Heart Transplantation

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Phase I/II Calcitriol in Lung Cancer

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Cyclosporine in Patients With Moderate COVID-19

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF

Analgesic Efficacy of Interscalene Nerve Block Versus Local Infiltration Analgesia Following Total Shoulder Arthroplasty

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia